📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. (2023)

First Author: Liu Z

Attributed to: 'SPIICA' - the Sao Paulo-Imperial College Immune Correlates in Arbovirus Infection Network funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1053/j.gastro.2022.10.010

PubMed Identifier: 36270334

Publication URI: http://europepmc.org/abstract/MED/36270334

Type: Journal Article/Review

Volume: 164

Parent Publication: Gastroenterology

Issue: 2

ISSN: 0016-5085